Seko, Yuya
Moriguchi, Michihisa
Takahashi, Aya
Yamaguchi, Kanji
Umemura, Atsushi
Okuda, Keiichiro
Kataoka, Seita
Unozawa, Hidemi
Kobayashi, Kazufumi
Ogasawara, Sadahisa
Sato, Rui
Tsuchiya, Satoshi
Watanabe, Shunji
Morimoto, Naoki
Iwai, Kenji
Aramaki, Takeshi
Kato, Naoya
Itoh, Yoshito
Article History
Received: 26 September 2021
Accepted: 13 November 2021
First Online: 15 January 2022
Declarations
:
: Sadahisa Ogasawara received honoraria from Bayer, Eisai, Eli Lilly, Chugai Pharma, AstraZeneca, and Merck & Co., Inc., consulting or advisory fees from Bayer, Eisai, Merck & Co., Inc., Chugai Pharma, Eli Lilly, and AstraZeneca, and research grants from Bayer, AstraZeneca, and Eisai. Michihisa Moriguchi received honoraria from Eisai, Bayer, Eli Lilly, and Chugai Pharma, and consulting or advisory fees from Eisai, Bayer, Eli Lilly, and Chugai Pharma. Naoki Morimoto received research grants from Eisai and AbbVie. Takeshi Aramaki received speaker’s bureau fees from Eli Lilly, Chugai Pharma, Termo, Eisai, and Taiho Pharma. Yoshito Itoh received speaker’s bureau fees from MSD, Gilead Sciences, and Abbvie GK, and research grants from MSD, Bristol Myers Squibb, and Scholarship grants from Takeda Pharmaceutical Company Limited, Eisai, Bayer, and Bristol Myers Squibb. Naoya Kato received honoraria from Bayer, Eisai, Sumitomo Dainippon Pharma, and Merck & Co., Inc., consulting or advisory fees from Bayer and Eisai, and research grants from Bayer and Eisai. The other authors have no conflicts of interest to declare.